Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dynavax (DVAX) and QuidelOrtho (QDEL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dynavax (DVAX – Research Report) and QuidelOrtho (QDEL – Research Report).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dynavax (DVAX)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on Dynavax. The company’s shares closed last Wednesday at $10.30, close to its 52-week low of $9.74.
According to TipRanks.com, Phipps is a 3-star analyst with an average return of
Currently, the analyst consensus on Dynavax is a Moderate Buy with an average price target of $22.67.
See today’s best-performing stocks on TipRanks >>
QuidelOrtho (QDEL)
In a report released today, Andrew Brackmann from William Blair maintained a Hold rating on QuidelOrtho. The company’s shares closed last Wednesday at $27.37.
According to TipRanks.com, Brackmann is a 5-star analyst with an average return of
QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $39.00, which is a 42.9% upside from current levels. In a report issued on October 29, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $29.00 price target.
Read More on DVAX:
Disclaimer & DisclosureReport an Issue
- Dynavax reports Q3 EPS 21c vs. 12c last year
- Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart
- Dynavax Technologies (DVAX) Q3 Earnings Cheat Sheet
- Dynavax Technologies Advances in Pneumonic Plague Vaccine Study
- Dynavax reports results from Phase 1/2 clinical trial of Z-1018
